Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.38 |
| ▸ | PDE4A | P27815 | 6/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274889 | 0.85 | SYK (0.42) | POLBERN1PDE4BPDE4APDE4C | |
| SCHEMBL275626 | 0.81 | POLB (0.44) | POLBERN1PDE4BPDE4APDE4C | |
| SCHEMBL274378 | 0.81 | POLB (0.44) | POLBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL275026 | 0.79 | POLB (0.45) | POLBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7662729 | 0.79 | POLB (0.45) | POLBERN1PDE4BPDE4APDE4C | |
| SCHEMBL14784352 | 0.78 | ERN1 (0.44) | POLBERN1PDE4BCSNK2A1HPGD | |
| SCHEMBL18003630 | 0.78 | POLB (0.49) | POLBERN1PDE4BPDE4APDE4C | |
| SCHEMBL11779563 | 0.77 | SRC (0.49) | POLBHPGD | |
| SCHEMBL20384188 | 0.76 | KMT2A (0.40) | POLBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5302703 | 0.75 | ALDH1A1 (0.50) | POLBPDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | POLB 2672/4885ERN1 2608/4885PDE4B 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.